Helus Pharma Inc. - Common Stock (NQ:HELP)

Helus Pharma to Host Investor Presentation on October 21, 2026

Today 7:30 EDT

From Helus Pharma Inc.

MissionIRNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Changes Legal Name from Cybin Inc.

Performance

52-Week Range 29.2% below 52-week high

10.72

3.7652W Low 15.1552W High

1 Week 14.1% below 1-week high

10.191W Low 12.481W High

Helus Pharma Inc. - Common Stock (HELP) traded between $3.76 and $15.15 over the past 52 weeks and last traded at $10.72, 29.2% below its 52-week high. Over the past week it ranged between $10.19 and $12.48.

Past 12 Months

-10.0%

-13.5%

+72.1%

+104.2%

+38.7%

1W -$1.19

1M -$1.67

3M +$4.49

6M +$5.47

YTD +$2.99

1Y +$2.99

HELP was +38.7% over the past year, +104.2% over six months, +38.7% year to date, -10.0% in the last week.

12 Months vs Market

HELP

+38.7%

DIA

+9.8%

SPY

+15.7%

QQQ

+23.7%

IWM

+13.7%

Over the past 12 months HELP returned +38.7% versus DIA (Dow) +9.8%, SPY (S&P 500) +15.7%, QQQ (Nasdaq 100) +23.7% and IWM (Russell 2000) +13.7%.

Volume & Liquidity 0.63× 3-mo avg

Today 1,116,987 3-mo avg 1.8M

1.2M

1.7M

1.8M

1.5M

YTD

1.3M

HELP most recently traded 1,116,987 shares against a 3-month average daily volume of 1.8M.

More News

October 01, 2026

Helus Pharma Announces Completion of Legal Name Change

October 01, 2026

Helus Pharma Eyes Q4 Phase III Data for HLP-003 in Major Depression ↗

September 24, 2026

TinyGemsBreaks – Helus Pharma (TM) (NASDAQ: HELP) (Cboe CA: HELP) Advances HLP003 Phase 3 Program, Targets Q4 2026 Topline Data

August 14, 2026

NetworkNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Reports Annual and Special Meeting Results, Legal Name Change Effective Oct. 1

September 23, 2026

Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change

September 22, 2026

NetworkNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) CEO to Participate in TD Cowen Neuropsychiatry Summit

September 22, 2026

Cybin Shareholders Weigh Helus Pharma Rebrand, Eight-Member Board ↗

September 22, 2026

Helus Pharma to Participate at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit

September 21, 2026

PsychedelicNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Presents HLP003 Data From MDD Program at Psych Congress 2026

September 21, 2026

Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026

September 21, 2026

Cybin Eyes Q4 Phase 3 Data for Depression Drug HLP003 ↗

September 21, 2026

Cybin Eyes Q4 Phase III Depression Readout as Psychedelic Pipeline Advances ↗

September 20, 2026

BioMedNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) CEO to Participate in Morgan Stanley Global Healthcare Conference

September 10, 2026

Helus Pharma to Participate at the Morgan Stanley 24th Annual Global Healthcare Conference in New York

September 10, 2026

InvestorNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) CEO to Participate in H.C. Wainwright 28th Annual Global Investment Conference

September 09, 2026

Helus Pharma to Participate at the H.C. Wainwright 28th Annual Global Investment Conference in New York

September 09, 2026

PsychedelicNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) to Participate in Cantor Global Healthcare Conference

September 03, 2026

Helus Pharma to Participate at the 2026 Cantor Global Healthcare Conference in New York

September 03, 2026

InvestorNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints Regina Donohue Chief People Officer and Suresh Durgam to Scientific Advisory Board

August 18, 2026

Helus Pharma Appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board

August 18, 2026

Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights

August 14, 2026

Cybin Conference: Helus CEO Eyes Q4 Phase III Depression Data for HLP003 ↗

August 14, 2026